ParkinsonCanadaV1, Main, Curation, bibRecord, 002F43

Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease

Identifieur interne : 002F43 ( Main/Curation ); précédent : 002F42; suivant : 002F44

Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease

Auteurs : Michael Iskedjian [Canada] ; Thomas R. Einarson [Canada]

Source :

PharmacoEconomics : (Auckland) [ 1170-7690 ] ; 2003.

RBID : Pascal:03-0206081

Descripteurs français

Pascal (Inist)
- Ropinirole, Lévodopa, Antiparkinsonien, Parkinson maladie, Chimiothérapie, Traitement, Homme, Economie santé, Analyse coût, Etude comparative, Agoniste, Récepteur dopaminergique D2, Stimulant dopaminergique, Analyse coût efficacité.
Wicri :
- geographic : Canada.
- topic : Homme.

English descriptors

KwdEn :
- Adult, Agonist, Antiparkinson Agents (economics), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Benserazide (economics), Benserazide (therapeutic use), Canada, Caregivers (economics), Chemotherapy, Comparative study, Cost Savings, Cost analysis, Cost efficiency analysis, D2 Dopamine receptor, Dopamine Agonists (economics), Dopamine Agonists (therapeutic use), Dopamine agonist, Drug Costs, Health Care Costs, Health economy, Human, Humans, Indoles (economics), Indoles (therapeutic use), Levodopa, Levodopa (economics), Levodopa (therapeutic use), Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (economics), Parkinson disease, Ropinirole, Treatment, Treatment Outcome.
MESH :
- chemical , economics : Antiparkinson Agents, Benserazide, Dopamine Agonists, Indoles, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Benserazide, Dopamine Agonists, Indoles, Levodopa.
- geographic : Canada.
- drug therapy : Parkinson Disease.
- economics : Caregivers, Parkinson Disease.
- Adult, Cost Savings, Drug Costs, Health Care Costs, Humans, Middle Aged, Treatment Outcome.

Abstract

Background: Not all patients with Parkinson's disease (PD) respond to levodopa and others develop dyskinesias. Ropinirole, a dopamine agonist, is associated with fewer dyskinesias than levodopa. Objective: To examine the economic impact of reducing dyskinesias using ropinirole instead of levodopa plus benserazide in PD was examined. The research question addressed was: is the added cost of ropinirole offset by savings due to avoided cases of dyskinesia? Methods: A cost-minimisation analysis was performed from both the societal and Ministry of Health (MoH) of Ontario, Canada perspectives, using 5-year data from a study of dyskinesia outcomes comparing ropinirole with levodopa plus benserazide. A predictive model was developed to capture resource utilisation over 5 years, such as medication costs, medical consultations, hospital admissions, nursing home admissions, caregiver time and productivity loss. The model was based on a previously reported clinical trial which determined dyskinesia rates to be 20% for ropinirole and 45% for levodopa. Standard costing lists were used, and costs were discounted at various rates. Constant 1999 Canadian dollars ($Can) were applied, and no increases were assumed over the time horizon of the analysis. A multivariate sensitivity analysis with changes in key parameters was also performed. Results: From a societal perspective, ropinirole was cost saving. From the MoH perspective, the analysis yielded an incremental expected daily cost/patient of $Can4.41 for substituting levodopa plus benserazide with ropinirole. Ropinirole resulted in daily savings/patient of $Can0.17 in non-drug healthcare costs. In the sensitivity analysis, the direction of results did not change despite changes of 15 to 20% in key parameters, suggesting robustness of the model. Conclusions: From the societal perspective, in comparison with levodopa plus benserazide, the added cost of ropinirole is offset by savings due to avoided cases of dyskinesia.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B32
to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000191
to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000965
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003351
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001474
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001474
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001474
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000272
to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000272
to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000272
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003184

Links to Exploration step

Pascal:03-0206081

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease</title>
<author><name sortKey="Iskedjian, Michael" sort="Iskedjian, Michael" uniqKey="Iskedjian M" first="Michael" last="Iskedjian">Michael Iskedjian</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Pharmldeas Research & Consulting Inc.</s1>
<s2>Oakville, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Pharmldeas Research & Consulting Inc.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Einarson, Thomas R" sort="Einarson, Thomas R" uniqKey="Einarson T" first="Thomas R." last="Einarson">Thomas R. Einarson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Pharmldeas Research & Consulting Inc.</s1>
<s2>Oakville, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Pharmldeas Research & Consulting Inc.</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0206081</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0206081 INIST</idno>
<idno type="RBID">Pascal:03-0206081</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B32</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000191</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000965</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000965</idno>
<idno type="wicri:doubleKey">1170-7690:2003:Iskedjian M:cost:analysis:of</idno>
<idno type="wicri:Area/Main/Merge">003351</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12515573</idno>
<idno type="wicri:Area/PubMed/Corpus">001474</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001474</idno>
<idno type="wicri:Area/PubMed/Curation">001474</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001474</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001474</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001474</idno>
<idno type="wicri:Area/Ncbi/Merge">000272</idno>
<idno type="wicri:Area/Ncbi/Curation">000272</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000272</idno>
<idno type="wicri:doubleKey">1170-7690:2003:Iskedjian M:cost:analysis:of</idno>
<idno type="wicri:Area/Main/Merge">003184</idno>
<idno type="wicri:Area/Main/Curation">002F43</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease</title>
<author><name sortKey="Iskedjian, Michael" sort="Iskedjian, Michael" uniqKey="Iskedjian M" first="Michael" last="Iskedjian">Michael Iskedjian</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Pharmldeas Research & Consulting Inc.</s1>
<s2>Oakville, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Pharmldeas Research & Consulting Inc.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Einarson, Thomas R" sort="Einarson, Thomas R" uniqKey="Einarson T" first="Thomas R." last="Einarson">Thomas R. Einarson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Pharmldeas Research & Consulting Inc.</s1>
<s2>Oakville, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Pharmldeas Research & Consulting Inc.</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">PharmacoEconomics : (Auckland)</title>
<title level="j" type="abbreviated">PharmacoEconomics : (Auckl. )</title>
<idno type="ISSN">1170-7690</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">PharmacoEconomics : (Auckland)</title>
<title level="j" type="abbreviated">PharmacoEconomics : (Auckl. )</title>
<idno type="ISSN">1170-7690</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Agonist</term>
<term>Antiparkinson Agents (economics)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Benserazide (economics)</term>
<term>Benserazide (therapeutic use)</term>
<term>Canada</term>
<term>Caregivers (economics)</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>Cost Savings</term>
<term>Cost analysis</term>
<term>Cost efficiency analysis</term>
<term>D2 Dopamine receptor</term>
<term>Dopamine Agonists (economics)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Dopamine agonist</term>
<term>Drug Costs</term>
<term>Health Care Costs</term>
<term>Health economy</term>
<term>Human</term>
<term>Humans</term>
<term>Indoles (economics)</term>
<term>Indoles (therapeutic use)</term>
<term>Levodopa</term>
<term>Levodopa (economics)</term>
<term>Levodopa (therapeutic use)</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (economics)</term>
<term>Parkinson disease</term>
<term>Ropinirole</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Benserazide</term>
<term>Dopamine Agonists</term>
<term>Indoles</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Benserazide</term>
<term>Dopamine Agonists</term>
<term>Indoles</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Caregivers</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Cost Savings</term>
<term>Drug Costs</term>
<term>Health Care Costs</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Ropinirole</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Parkinson maladie</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Economie santé</term>
<term>Analyse coût</term>
<term>Etude comparative</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D2</term>
<term>Stimulant dopaminergique</term>
<term>Analyse coût efficacité</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Not all patients with Parkinson's disease (PD) respond to levodopa and others develop dyskinesias. Ropinirole, a dopamine agonist, is associated with fewer dyskinesias than levodopa. Objective: To examine the economic impact of reducing dyskinesias using ropinirole instead of levodopa plus benserazide in PD was examined. The research question addressed was: is the added cost of ropinirole offset by savings due to avoided cases of dyskinesia? Methods: A cost-minimisation analysis was performed from both the societal and Ministry of Health (MoH) of Ontario, Canada perspectives, using 5-year data from a study of dyskinesia outcomes comparing ropinirole with levodopa plus benserazide. A predictive model was developed to capture resource utilisation over 5 years, such as medication costs, medical consultations, hospital admissions, nursing home admissions, caregiver time and productivity loss. The model was based on a previously reported clinical trial which determined dyskinesia rates to be 20% for ropinirole and 45% for levodopa. Standard costing lists were used, and costs were discounted at various rates. Constant 1999 Canadian dollars ($Can) were applied, and no increases were assumed over the time horizon of the analysis. A multivariate sensitivity analysis with changes in key parameters was also performed. Results: From a societal perspective, ropinirole was cost saving. From the MoH perspective, the analysis yielded an incremental expected daily cost/patient of $Can4.41 for substituting levodopa plus benserazide with ropinirole. Ropinirole resulted in daily savings/patient of $Can0.17 in non-drug healthcare costs. In the sensitivity analysis, the direction of results did not change despite changes of 15 to 20% in key parameters, suggesting robustness of the model. Conclusions: From the societal perspective, in comparison with levodopa plus benserazide, the added cost of ropinirole is offset by savings due to avoided cases of dyskinesia.</div>
</front>
</TEI>
<double idat="1170-7690:2003:Iskedjian M:cost:analysis:of"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease</title>
<author><name sortKey="Iskedjian, Michael" sort="Iskedjian, Michael" uniqKey="Iskedjian M" first="Michael" last="Iskedjian">Michael Iskedjian</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Pharmldeas Research & Consulting Inc.</s1>
<s2>Oakville, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Pharmldeas Research & Consulting Inc.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Einarson, Thomas R" sort="Einarson, Thomas R" uniqKey="Einarson T" first="Thomas R." last="Einarson">Thomas R. Einarson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Pharmldeas Research & Consulting Inc.</s1>
<s2>Oakville, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Pharmldeas Research & Consulting Inc.</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0206081</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0206081 INIST</idno>
<idno type="RBID">Pascal:03-0206081</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B32</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000191</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000965</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000965</idno>
<idno type="wicri:doubleKey">1170-7690:2003:Iskedjian M:cost:analysis:of</idno>
<idno type="wicri:Area/Main/Merge">003351</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease</title>
<author><name sortKey="Iskedjian, Michael" sort="Iskedjian, Michael" uniqKey="Iskedjian M" first="Michael" last="Iskedjian">Michael Iskedjian</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Pharmldeas Research & Consulting Inc.</s1>
<s2>Oakville, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Pharmldeas Research & Consulting Inc.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Einarson, Thomas R" sort="Einarson, Thomas R" uniqKey="Einarson T" first="Thomas R." last="Einarson">Thomas R. Einarson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Pharmldeas Research & Consulting Inc.</s1>
<s2>Oakville, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Pharmldeas Research & Consulting Inc.</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">PharmacoEconomics : (Auckland)</title>
<title level="j" type="abbreviated">PharmacoEconomics : (Auckl. )</title>
<idno type="ISSN">1170-7690</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">PharmacoEconomics : (Auckland)</title>
<title level="j" type="abbreviated">PharmacoEconomics : (Auckl. )</title>
<idno type="ISSN">1170-7690</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>Cost analysis</term>
<term>Cost efficiency analysis</term>
<term>D2 Dopamine receptor</term>
<term>Dopamine agonist</term>
<term>Health economy</term>
<term>Human</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Ropinirole</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Ropinirole</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Parkinson maladie</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Economie santé</term>
<term>Analyse coût</term>
<term>Etude comparative</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D2</term>
<term>Stimulant dopaminergique</term>
<term>Analyse coût efficacité</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Not all patients with Parkinson's disease (PD) respond to levodopa and others develop dyskinesias. Ropinirole, a dopamine agonist, is associated with fewer dyskinesias than levodopa. Objective: To examine the economic impact of reducing dyskinesias using ropinirole instead of levodopa plus benserazide in PD was examined. The research question addressed was: is the added cost of ropinirole offset by savings due to avoided cases of dyskinesia? Methods: A cost-minimisation analysis was performed from both the societal and Ministry of Health (MoH) of Ontario, Canada perspectives, using 5-year data from a study of dyskinesia outcomes comparing ropinirole with levodopa plus benserazide. A predictive model was developed to capture resource utilisation over 5 years, such as medication costs, medical consultations, hospital admissions, nursing home admissions, caregiver time and productivity loss. The model was based on a previously reported clinical trial which determined dyskinesia rates to be 20% for ropinirole and 45% for levodopa. Standard costing lists were used, and costs were discounted at various rates. Constant 1999 Canadian dollars ($Can) were applied, and no increases were assumed over the time horizon of the analysis. A multivariate sensitivity analysis with changes in key parameters was also performed. Results: From a societal perspective, ropinirole was cost saving. From the MoH perspective, the analysis yielded an incremental expected daily cost/patient of $Can4.41 for substituting levodopa plus benserazide with ropinirole. Ropinirole resulted in daily savings/patient of $Can0.17 in non-drug healthcare costs. In the sensitivity analysis, the direction of results did not change despite changes of 15 to 20% in key parameters, suggesting robustness of the model. Conclusions: From the societal perspective, in comparison with levodopa plus benserazide, the added cost of ropinirole is offset by savings due to avoided cases of dyskinesia.</div>
</front>
</TEI>
</INIST>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.</title>
<author><name sortKey="Iskedjian, Michael" sort="Iskedjian, Michael" uniqKey="Iskedjian M" first="Michael" last="Iskedjian">Michael Iskedjian</name>
<affiliation wicri:level="1"><nlm:affiliation>PharmIdeas Research & Consulting Inc., Oakville, Ontario, Canada. skedji@pharmideas.com</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>PharmIdeas Research & Consulting Inc., Oakville, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Einarson, Thomas R" sort="Einarson, Thomas R" uniqKey="Einarson T" first="Thomas R" last="Einarson">Thomas R. Einarson</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:12515573</idno>
<idno type="pmid">12515573</idno>
<idno type="wicri:Area/PubMed/Corpus">001474</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001474</idno>
<idno type="wicri:Area/PubMed/Curation">001474</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001474</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001474</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001474</idno>
<idno type="wicri:Area/Ncbi/Merge">000272</idno>
<idno type="wicri:Area/Ncbi/Curation">000272</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000272</idno>
<idno type="wicri:doubleKey">1170-7690:2003:Iskedjian M:cost:analysis:of</idno>
<idno type="wicri:Area/Main/Merge">003184</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.</title>
<author><name sortKey="Iskedjian, Michael" sort="Iskedjian, Michael" uniqKey="Iskedjian M" first="Michael" last="Iskedjian">Michael Iskedjian</name>
<affiliation wicri:level="1"><nlm:affiliation>PharmIdeas Research & Consulting Inc., Oakville, Ontario, Canada. skedji@pharmideas.com</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>PharmIdeas Research & Consulting Inc., Oakville, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Einarson, Thomas R" sort="Einarson, Thomas R" uniqKey="Einarson T" first="Thomas R" last="Einarson">Thomas R. Einarson</name>
</author>
</analytic>
<series><title level="j">PharmacoEconomics</title>
<idno type="ISSN">1170-7690</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Antiparkinson Agents (economics)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Benserazide (economics)</term>
<term>Benserazide (therapeutic use)</term>
<term>Canada</term>
<term>Caregivers (economics)</term>
<term>Cost Savings</term>
<term>Dopamine Agonists (economics)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Drug Costs</term>
<term>Health Care Costs</term>
<term>Humans</term>
<term>Indoles (economics)</term>
<term>Indoles (therapeutic use)</term>
<term>Levodopa (economics)</term>
<term>Levodopa (therapeutic use)</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (economics)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Benserazide</term>
<term>Dopamine Agonists</term>
<term>Indoles</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Benserazide</term>
<term>Dopamine Agonists</term>
<term>Indoles</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Caregivers</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Cost Savings</term>
<term>Drug Costs</term>
<term>Health Care Costs</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Not all patients with Parkinson's disease (PD) respond to levodopa and others develop dyskinesias. Ropinirole, a dopamine agonist, is associated with fewer dyskinesias than levodopa.</div>
</front>
</TEI>
</PubMed>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F43 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002F43 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:03-0206081
   |texte=   Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease

Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri